文献速递血脂与心血管预防

早期检测心脏生物标志物升高以优化COVID-19患者风险分层

Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19.
PubMed 文献 · Heart · 2020-08-14

在意大利一家三级中心连续纳入397例确诊COVID-19患者,于入院24小时内检测高敏肌钙蛋白I(hs-TnI)和B型利钠肽(BNP),按两者是否升高分组比较全因死亡率。结果显示hs-TnI和/或BNP升高者死亡率显著高于正常者,两者同时升高是全因死亡的独立预测因素。

要点

  • 入院24小时内hs-TnI和BNP同时升高者死亡率55.6%,显著高于生物标志物正常者6.25%。
  • hs-TnI和BNP同时升高是全因死亡的独立预测因素(OR 3.24,95%CI 1.06–9.93)。
  • 建议COVID-19患者入院时系统评估心脏生物标志物以优化风险分层。

核心结论

  • 早期检测hs-TnI和BNP升高可预测COVID-19患者死亡,应于入院时系统评估以优化风险分层。

研究设计与样本

  • 意大利Rozzano-Milan的Humanitas临床与研究医院单中心队列观察性分析,连续纳入截至2020年4月1日确诊COVID-19患者397例。
  • 按入院24小时内hs-TnI、BNP是否高于正常上限分组,主要结局为全因死亡率。

主要发现

  • 入院时208例(52.4%)心脏生物标志物正常,90例(22.7%)hs-TnI和BNP均升高,59例(14.9%)仅BNP升高,40例(10.1%)仅hs-TnI升高。
  • 与生物标志物未升高者死亡率6.25%相比,hs-TnI升高者死亡率22.5%(OR 4.35,95%CI 1.72–11.04),BNP升高者33.9%(OR 7.37,95%CI 3.53–16.75),两者均升高者55.6%(OR 18.75,95%CI 9.32–37.71)。
  • 多因素分析显示hs-TnI和BNP同时升高是全因死亡的强独立预测因素(OR 3.24,95%CI 1.06–9.93)。

关键数值与推荐

  • 生物标志物升高定义为高于正常上限,于入院24小时内检测。
  • hs-TnI和BNP同时升高者全因死亡风险独立增加(OR 3.24,95%CI 1.06–9.93)。

临床怎么用

  • COVID-19患者入院时应系统检测hs-TnI和BNP,以识别高危患者并优化风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Risk stratification is crucial to optimise treatment strategies in patients with COVID-19. We aimed to evaluate the impact on mortality of an early assessment of cardiac biomarkers in patients with COVID-19. METHODS: Humanitas Clinical and Research Hospital (Rozzano-Milan, Lombardy, Italy) is a tertiary centre that has been converted to the management of COVID-19. Patients with confirmed COVID-19 were entered in a dedicated database for cohort observational analyses. Outcomes were stratified according to elevated levels (ie, above the upper level of normal) of high-sensitivity cardiac troponin I (hs-TnI), B-type natriuretic peptide (BNP) or both measured within 24 hours after hospital admission. The primary outcome was all-cause mortality. RESULTS: A total of 397 consecutive patients with COVID-19 were included up to 1 April 2020. At the time of hospital admission, 208 patients (52.4%) had normal values for cardiac biomarkers, 90 (22.7%) had elevated both hs-TnI and BNP, 59 (14.9%) had elevated only BNP and 40 (10.1%) had elevated only hs-TnI. The rate of mortality was higher in patients with elevated hs-TnI (22.5%, OR 4.35, 95% CI 1.72 to 11.04), BNP (33.9%, OR 7.37, 95% CI 3.53 to 16.75) or both (55.6%, OR 18.75, 95% CI 9.32 to 37.71) as compared with those without elevated cardiac biomarkers (6.25%). A multivariate analysis identified concomitant elevation of both hs-TnI and BNP as a strong independent predictor of all-cause mortality (OR 3.24, 95% CI 1.06 to 9.93). CONCLUSIONS: An early detection of elevated hs-TnI and BNP predicts mortality in patients with COVID-19. Cardiac biomarkers should be systematically assessed in patients with COVID-19 at the time of hospital admission in order to optimise risk stratification.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Stefanini GG, Chiarito M, Ferrante G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020. PMID: 32817312. doi:10.1136/heartjnl-2020-317322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。